IPSEN |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 120.5 EUR | -0.74% |
|
+0.50% | +11.68% |
| 05-14 | Ipsen: share price up, analyst raises target | CF |
| 05-14 | IPSEN : Barclays raises its target price | CF |
ETFs positioned on Ipsen
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 234 M€ | +5.85% | - | |
| 0.00% | 306 M€ | +6.47% | - | |
| 0.00% | 39 M€ | +6.61% | - | |
| 0.00% | 1 M€ | 0.00% | - | |
| 0.00% | 29 M€ | -1.43% | - | |
| 0.00% | 146 M€ | -1.86% | - | |
| 0.00% | 25 M€ | -2.62% | - |
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
121.4
EUR
Average target price
126.3
EUR
Spread / Average Target
+4.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.68% | 10.9B | |
| +32.67% | 694B | |
| +29.22% | 593B | |
| -1.63% | 371B | |
| +19.91% | 331B | |
| +6.36% | 290B | |
| +14.00% | 239B | |
| -3.15% | 209B | |
| +9.86% | 209B | |
| +8.04% | 169B |
- Stock Market
- Equities
- IPN Stock
- Funds and ETFs Ipsen